Pramlintide

Pramlintide is a synthetic 37-amino acid analog of amylin, a peptide hormone that is co-secreted with insulin from pancreatic beta cells in response to food intake. In individuals with diabetes — particularly type 1 diabetes where beta cells are destroyed — amylin secretion is deficient or absent, contributing to postprandial hyperglycemia. Pramlintide was designed with three proline substitutions that prevent the amyloid aggregation tendency of native amylin while preserving its biological activity.

Approved by the FDA in 2005, pramlintide (marketed as Symlin) is the only amylin analog approved for clinical use and the first non-insulin, non-glucose-lowering hormone therapy approved as an adjunct to mealtime insulin. It works through three complementary mechanisms: slowing gastric emptying (reducing the rate of glucose entry into the bloodstream), suppressing postprandial glucagon secretion (which is inappropriately elevated in diabetes), and promoting satiety (reducing food intake and body weight).

Clinical trials demonstrated that the addition of pramlintide to insulin therapy reduces postprandial glucose excursions, lowers HbA1c by approximately 0.3-0.6%, and promotes modest weight loss of 1-3 kg. The weight loss effect is particularly valuable in type 2 diabetes patients on insulin, where weight gain is common, and in type 1 diabetes patients seeking better postprandial control without the weight gain associated with intensive insulin therapy.

Despite its unique mechanism and clinical benefits, pramlintide adoption has been limited by the need for separate injections at each meal (in addition to insulin), a complex dose titration protocol, and a significant risk of insulin-induced hypoglycemia (particularly in type 1 diabetes), which requires proactive insulin dose reduction when starting pramlintide. Research into co-formulations of pramlintide with insulin has been ongoing to address the multiple-injection burden.